EUVIMEDEUVIMED entdecken
Crossref

Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds

Zhirong Ouyang, Muye Ma, Ziwen Zhang, Hongyu Wu, Yongxing Xue, Yuting Jian, Kai Yin, Shaokun Yu, Chunchang Zhao iD, Wei Guo, Xianfeng Gu iD

Journal of Medicinal Chemistry · 11.01.2024 · 67 (1) · 433-449

DOI: 10.1021/acs.jmedchem.3c01634 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 19.12.2023. Verfasst von Zhirong Ouyang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201301, China. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Atherosclerosis. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Pudong New Area Science and Technology Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proprotein convertase subtilisin/kexin type-9 (PCSK9), a secreted protein that is synthesized and spontaneously cleaved in the endoplasmic reticulum, has become a hot lipid-lowering target chased by pharmaceutical companies in recent years. Autophagosome-tethering compounds (ATTECs) represent a new strategy to degrade targeted biomolecules. Here, we designed and synthesized PCSK9·ATTECs that are capable of lowering PCSK9 levels via autophagy in vivo, providing the first report of the degradation of a secreted protein by ATTECs. OY3, one of the PCSK9·ATTECs synthesized, shows greater potency to reduce plasma low-density lipoprotein cholesterol (LDL-C) levels and improve atherosclerosis symptoms than treatment with the same dose of simvastatin. OY3 also significantly reduces the high expression of PCSK9 caused by simvastatin administration in atherosclerosis model mice and subsequently increases the level of low-density lipoprotein receptor, promoting simvastatin to clear plasma LDL-C and alleviate atherosclerosis symptoms. Thus, we developed a new candidate compound to treat atherosclerosis that could also promote statin therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proprotein Convertase 9AtherosclerosisMiceAnimalsCholesterol, LDLSimvastatinReceptors, LDLAutophagy

Substanzen

PCSK9 protein, humanProprotein Convertase 9Cholesterol, LDLSimvastatinReceptors, LDL

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201301, China.
  • Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201301, China.
  • Key Laboratory for Advanced Materials and Feringa Nobel Prize Scientist Joint Research Center, Institute of Fine Chemicals, School of Chemistry and Molecular Engineering, Frontiers Science Center for Materiobiology and…

ORCID-Profile: Chunchang Zhao, Xianfeng Gu

Förderung

  • National Natural Science Foundation of China
  • Shanghai Pudong New Area Science and Technology Development

Zitieren

APA

Ouyang, Z., Ma, M., Zhang, Z., Wu, H., Xue, Y., Jian, Y., Yin, K., Yu, S., Zhao, C., Guo, W., & Gu, X. (2024). Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds. Journal of Medicinal Chemistry, 67(1), 433-449. https://doi.org/10.1021/acs.jmedchem.3c01634

Vancouver

Ouyang Z, Ma M, Zhang Z, Wu H, Xue Y, Jian Y, et al. Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds. Journal of Medicinal Chemistry. 2024;67(1):433-449. doi:10.1021/acs.jmedchem.3c01634

BibTeX
@article{Ouyang2024,
  author = {Ouyang, Zhirong and Ma, Muye and Zhang, Ziwen and Wu, Hongyu and Xue, Yongxing and Jian, Yuting and Yin, Kai and Yu, Shaokun and Zhao, Chunchang and Guo, Wei and Gu, Xianfeng},
  title = {Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {1},
  pages = {433--449},
  doi = {10.1021/acs.jmedchem.3c01634}
}
Kostenlos starten →